Results 41 to 50 of about 3,116,614 (307)

Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC. [PDF]

Front Pharmacol
Background Sorafenib is a first-line treatment for hepatocellular carcinoma (HCC); however, acquired resistance often results in a poor prognosis, indicating a need for more effective therapies.
Li X, Chen S, Shi Y, Wang Y, Wang X, Lin Q, Wu C, Fang W, Sun P, Ma L.   +9 more
europepmc   +2 more sources

Intracellular magnetic hyperthermia reverses sorafenib resistance in hepatocellular carcinoma through its action on signaling pathways

iScience
Summary: Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), unfortunately encounters resistance in most patients, leading to disease progression.
Hugang Li, Zirui Ye, Xun Wang, Jianlan Yuan, Jingyi Guo, Chen Liu, Bin Yan, Haiming Fan, Yi Lyu, Xiaoli Liu   +9 more
doaj   +2 more sources

Mechanisms of Sorafenib Resistance in HCC Culture Relate to the Impaired Membrane Expression of Organic Cation Transporter 1 (OCT1)

Journal of Hepatocellular Carcinoma
Srinivas Chava,1 Nergiz Ekmen,2 Pauline Ferraris,1 Yucel Aydin,2 Krzysztof Moroz,1 Tong Wu,1 Swan N Thung,3 Srikanta Dash1,2,4 1Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA; 2Department ...
Chava S, Ekmen N, Ferraris P, Aydin Y, Moroz K, Wu T, Thung SN, Dash S   +7 more
doaj   +2 more sources

Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma.

Biomedicine & Pharmacotherapy, 2023
Sorafenib, a multi-kinase inhibitor, has been approved for cancer treatment for decades, especially hepatocellular carcinoma (HCC). Although sorafenib produced substantial clinical benefits in the initial stage, a large proportion of cancer patients acquired drug resistance in subsequent treatment, which always disturbs clinical physicians.
Shuhua Wei, Fenghua Wei, Mengyuan Li, Yuhan Yang, Jing-Wei Zhang, Chunxiao Li, Junjie Wang   +6 more
semanticscholar   +3 more sources

Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma. [PDF]

Oncol Res
Hepatocellular carcinoma (HCC) poses a significant threat to human health. Resistance to sorafenib in the chemotherapy of HCC is a common and significant issue that profoundly impacts clinical treatment.
Zhuang M, Zhang X, Li LU, Wen L, Qin J.
europepmc   +2 more sources

MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy

Acta Biochimica Polonica, 2023
OBJECTIVE Sorafenib is the first-line treatment for hepatocellular carcinoma (HCC), but its efficacy is limited by the drug resistance of HCC cells. MiR-375 has been shown to be an inhibitor of autophagy that contributes to sorafenib resistance of HCC ...
Dan Wang, Jingbo Yang
openalex   +3 more sources

Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma

Cellular Physiology and Biochemistry, 2017
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and prognosis remains unsatisfactory since the disease is often diagnosed at the advanced stages.
Ting Sun, Hongchun Liu, Liang Ming
doaj   +2 more sources

Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation [PDF]

Frontiers in Pharmacology
BackgroundCurcumol, a bioactive sesquiterpenoid extracted from traditional Chinese medicine (TCM), has demonstrated potential in overcoming tumor drug resistance.
Ni Zhang, Xinchen Tian, Fen Liu, Xiaohan Jin, Xiaohan Jin, Jiaqi Zhang, Lingli Hao, Shulong Jiang, Shulong Jiang, Qingbin Liu, Qingbin Liu   +10 more
doaj   +2 more sources

Neuropilin-2 (NRP2) mediates sorafenib resistance in clear cell renal cell carcinoma via the NRP2/NF-κB/TNFα axis. [PDF]

Am J Cancer Res
Gu R, Long Q, He T, Li W, Zhang Z, Zhang T, Xu D, Li Z, Liu Q.   +8 more
europepmc   +3 more sources

Increased CAPG inhibits ferroptosis to drive tumor proliferation and sorafenib resistance in hepatocellular carcinoma via the WDR74-p53-SLC7A11 pathway. [PDF]

Int J Biol Sci
Quan B, Yao F, Liu W, Tang B, Li M, Lu S, Li J, Chen R, Ren Z, Yin X.   +9 more
europepmc   +3 more sources